Effects of Dapagliflozin in People without Diabetes and with Microalbuminuria-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effects of Dapagliflozin in People without Diabetes and with Microalbuminuria

Published:2022-11 Issue:11 Volume:17 Page:1665-1668
ISSN:1555-9041
Container-title:Clinical Journal of the American Society of Nephrology
language:en
Short-container-title:CJASN

Author:

Heerspink Hiddo J.L.,Chertow Glenn M.,Jongs Niels,Correa-Rotter Ricardo,Rossing Peter,Sjöström C. David,Langkilde Anna Maria,Wheeler David C.

Funder

AstraZeneca

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation,Nephrology,Critical Care and Intensive Care Medicine,Epidemiology

Reference5 articles.

1. Dapagliflozin in patients with chronic kidney disease;Heerspink;N Engl J Med,2020

2. Rationale and protocol of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial;Heerspink;Nephrol Dial Transplant,2020

3. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: A prespecified analysis from the DAPA-CKD trial;Jongs;Lancet Diabetes Endocrinol,2021

4. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: A prespecified analysis from the DAPA-CKD trial;Heerspink;Lancet Diabetes Endocrinol,2021

5. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial;Nephrol Dial Transplant,2022

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dapagliflozin treatment of patients with chronic kidney disease without diabetes across different albuminuria levels (OPTIMISE-CKD);Clinical Kidney Journal;2024-04-04

2. Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial;Clinical Kidney Journal;2024-02-01

3. Combination therapy with kidney protective therapies: optimizing the benefits?;Current Opinion in Nephrology & Hypertension;2023-09-28

4. Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence;Kidney Diseases;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3